L Monteagudo Moreno, P Cía Blasco, M Malo Urries, A Nuez Polo, C Marín Zaldívar
{"title":"Predictors of response in patients with traumatic peripheral neuropathic pain treated with the 8% capsaicin patch.","authors":"L Monteagudo Moreno, P Cía Blasco, M Malo Urries, A Nuez Polo, C Marín Zaldívar","doi":"10.1016/j.redare.2025.501880","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Neuropathic pain (NP) is a widespread, complex disorder that responds differently to pharmacological treatment. The aim of this study was to identify the baseline characteristics of good response to capsaicin 8% patch in patients with trauma-induced peripheral neuropathic pain (PNP).</p><p><strong>Materials and methods: </strong>We performed a prospective, longitudinal, open-label study in 31 patients with PNP treated with 1-3 applications of the capsaicin 8% patch for 52 weeks. Response to treatment was defined as a reduction in the Visual Analogue Scale (VAS) score compared to baseline. Data from responders and non-responders were compared at the start (month 1) and end (month 12) of treatment. Logistic regression was used to identify predictors of treatment response.</p><p><strong>Results: </strong>At month 1, responders (n = 17) had significantly larger treatment areas (155.18 cm<sup>2</sup> vs. 59.21 cm<sup>2</sup>; p = 0.004) and reported greater pain relief with treatments received in the previous week in the brief pain questionnaire (34.7% vs. 14.3%; p = 0.023). At month 12, significant predictors included cold allodynia (OR 8; p = 0.030), positive for painful cold in the DN4 questionnaire (OR 7.936; p = 0.019), no penetrating pain (OR 16.800; p = 0.009), and pain interference with work score <7.5 (OR 7.917; p = 0.019).</p><p><strong>Conclusions: </strong>This study makes a significant contribution to the management of post-traumatic peripheral neuropathic pain by providing tools to personalise treatment and optimize available resources.</p>","PeriodicalId":94196,"journal":{"name":"Revista espanola de anestesiologia y reanimacion","volume":" ","pages":"501880"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de anestesiologia y reanimacion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.redare.2025.501880","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: Neuropathic pain (NP) is a widespread, complex disorder that responds differently to pharmacological treatment. The aim of this study was to identify the baseline characteristics of good response to capsaicin 8% patch in patients with trauma-induced peripheral neuropathic pain (PNP).
Materials and methods: We performed a prospective, longitudinal, open-label study in 31 patients with PNP treated with 1-3 applications of the capsaicin 8% patch for 52 weeks. Response to treatment was defined as a reduction in the Visual Analogue Scale (VAS) score compared to baseline. Data from responders and non-responders were compared at the start (month 1) and end (month 12) of treatment. Logistic regression was used to identify predictors of treatment response.
Results: At month 1, responders (n = 17) had significantly larger treatment areas (155.18 cm2 vs. 59.21 cm2; p = 0.004) and reported greater pain relief with treatments received in the previous week in the brief pain questionnaire (34.7% vs. 14.3%; p = 0.023). At month 12, significant predictors included cold allodynia (OR 8; p = 0.030), positive for painful cold in the DN4 questionnaire (OR 7.936; p = 0.019), no penetrating pain (OR 16.800; p = 0.009), and pain interference with work score <7.5 (OR 7.917; p = 0.019).
Conclusions: This study makes a significant contribution to the management of post-traumatic peripheral neuropathic pain by providing tools to personalise treatment and optimize available resources.